TLP
ONCT

Tri Locum Partners’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Tri Locum Partners’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14,286
Closed -$1.4M – 80
2020
Q4 		$1.4M Buy
+14,286
New +$904K 0.51% 31

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return

Tri Locum Partners's ONCT Position: Q1 2021 in Review

Tri Locum Partners sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2021, closing a stake of 14,286 shares — an estimated $1.4M sold.

Tri Locum Partners first reported a position in ONCT in Q4 2020 and held it in 1 quarter. The position peaked at $1.4M in Q4 2020. 64 funds tracked by Wall St. Rank hold ONCT as of Q1 2021.

  • Tri Locum Partners reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Tri Locum Partners sold 14,286 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $1.4M.
  • Tri Locum Partners first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Tri Locum Partners's Oncternal Therapeutics, Inc. Common Stock position peaked at $1.4M in Q4 2020.
  • 64 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Tri Locum Partners's 13F filing for Q1 2021, filed 17 May 2021.